MBX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

7 Analyst Rating

Wall Street analysts forecast MBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBX is 64.00 USD with a low forecast of 45.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

45.00

Averages

64.00

High

80.00

Current: 0.000

Low

45.00

Averages

64.00

High

80.00

UBS

initiated

$60

2026-01-07

New

Reason

UBS

Price Target

$60

2026-01-07

New

initiated

Reason

UBS initiated coverage of MBX Biosciences (MBX) with a Buy rating and $60 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Stifel

Annabel Samimy

Buy

maintain

$45 -> $50

2025-12-19

Reason

Stifel

Annabel Samimy

Price Target

$45 -> $50

2025-12-19

maintain

Buy

Reason

Stifel analyst Annabel Samimy raised the firm's price target on MBX Biosciences to $50 from $45 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst's Biopharma coverage.

Goldman

Sell

initiated

2025-12-04

Reason

Goldman

Price Target

2025-12-04

initiated

Sell

Reason

MBX Biosciences drops 4% in premarket trading after Goldman initiates with Sell

Goldman Sachs

Sell

initiated

$18

2025-12-04

Reason

Goldman Sachs

Price Target

$18

2025-12-04

initiated

Sell

Reason

Goldman Sachs initiated coverage of MBX Biosciences with a Sell rating and $18 price target. The key issue for MBX over the next year will be whether its platform shows validity beyond canvuparatide, with upcoming Phase 2a Post-Bariatric Hypoglycemia data in 2Q26 serving as the next major catalyst but likely falling short of demonstrating meaningful differentiation and driving a challenging risk/benefit profile, the analyst tells investors in a research note. While canvuparatide's long-term extension data appear relatively de-risked, and early-stage obesity data in 4Q26 could help validate the platform, these programs remain early, supporting a cautious outlook despite recent stock strength and potential upside from future business development, Goldman says.

Guggenheim

Buy

maintain

$84 -> $77

2025-11-10

Reason

Guggenheim

Price Target

$84 -> $77

2025-11-10

maintain

Buy

Reason

Guggenheim lowered the firm's price target on MBX Biosciences to $77 from $84 and keeps a Buy rating on the shares following Q3 earnings. The firm, which reiterates "Top Pick Designation" as MBX advances towards a catalyst-rich 2026, updated its model for Q3 results and the September financing, which drives its price target change.

Mizuho

Uy Ear

Outperform

maintain

$56 -> $57

2025-11-07

Reason

Mizuho

Uy Ear

Price Target

$56 -> $57

2025-11-07

maintain

Outperform

Reason

Mizuho analyst Uy Ear raised the firm's price target on MBX Biosciences to $57 from $56 and keeps an Outperform rating on the shares.

Valuation Metrics

The current forward P/E ratio for MBX Biosciences Inc (MBX.O) is -9.62, compared to its 5-year average forward P/E of -5.81. For a more detailed relative valuation and DCF analysis to assess MBX Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.81

Current PE

-9.62

Overvalued PE

-3.23

Undervalued PE

-8.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.05

Current EV/EBITDA

-7.06

Overvalued EV/EBITDA

-0.23

Undervalued EV/EBITDA

-5.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MBX News & Events

Events Timeline

No data

News

2.0

01-07Benzinga

Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release

3.5

01-07Yahoo Finance

Microbix Launches First Recombinant Antigen Product for COVID-19 Testing

1.0

2025-12-15Newsfilter

MBX Biosciences to Present Novel Therapies at 44th J.P. Morgan Healthcare Conference

People Also Watch

Frequently Asked Questions

What is MBX Biosciences Inc (MBX) stock price today?

The current price of MBX is 31.66 USD — it has increased 3.06 % in the last trading day.

What is MBX Biosciences Inc (MBX)'s business?

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

What is the price predicton of MBX Stock?

What is MBX Biosciences Inc (MBX)'s revenue for the last quarter?

MBX Biosciences Inc revenue for the last quarter amounts to -23.93M USD, increased 22.00 % YoY.

What is MBX Biosciences Inc (MBX)'s earnings per share (EPS) for the last quarter?

MBX Biosciences Inc. EPS for the last quarter amounts to -21935000.00 USD, increased 49.00 % YoY.

What changes have occurred in the market's expectations for MBX Biosciences Inc (MBX)'s fundamentals?

The market is revising No Change the revenue expectations for MBX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 112.34%.

How many employees does MBX Biosciences Inc (MBX). have?

MBX Biosciences Inc (MBX) has 43 emplpoyees as of January 10 2026.

What is MBX Biosciences Inc (MBX) market cap?

Today MBX has the market capitalization of 1.42B USD.